Sign in
OCUL Stock Price, Chart, Stats & News
Ocular Therapeutix Inc
Save
Ocular Therapeutix Inc (OCUL) does not currently pay a dividend.
1.91B
Market cap
–
Current P/E
–
Forward P/E
OCUL chart
1M
3M
1Y
5Y
Loading chart...
Fundamentals
Gross margin | 87.35% |
Operating margin | -519.75% |
Pretax margin | -511.90% |
Net margin | -511.90% |
Effective tax rate | – |
ROA | -32.91% |
ROE | -71.66% |
D/E | 0.12x |
Interest coverage ratio | -22.82x |
OCUL valuation
P/E | – |
P/S | 31.64x |
P/B | 2.57x |
P/CF | -8.21x |
P/FCF | -7.58x |
P/OCF | -8.21x |
PEG | -0.06x |
EV multiple | -9.22x |
About
Ocular Therapeutix, Inc. is a biopharmaceutical company specializing in the creation, advancement, and commercialization of ophthalmic treatments. Their innovative approach leverages a proprietary bioresorbable hydrogel technology to address a range of eye diseases and conditions. The company currently offers two key products: ReSure Sealant, an ophthalmic device designed to prevent fluid leakage from corneal incisions after cataract surgery, and DEXTENZA, a dexamethasone-based ophthalmic insert used to manage post-surgical inflammation and pain in the eye, as well as to treat allergic conjunctivitis.
Similar securities
Based on sector and market capitalization
Report issue